Our previous report indicated that COL11A1 enhances cell sensitivity to anti-cancer drugs via the activation of the Akt/c/EBPβ pathway in concert with attenuated PDK1 ubiquitination and degradation (Wu et al., 2015). Here, AKT1 is linked to cancer.